Treats Attention Deficit Hyperactivity Disorder (ADHD). ANDA 217269, held by Alembic. Guanfacine Hydrochloride.
As of Nov 21, 2026, ANDA 217269 (Guanfacine Hydrochloride), held by Alembic, was first approved by FDA on Aug 7, 2023, with 0 approved supplements and 0 published complete response letters.
Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 7, 2023 | Original application | Approved | None posted |
| Guanfacine HydrochlorideEQ 1MG BASE ยท tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 2MG BASE ยท tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 3MG BASE ยท tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 4MG BASE ยท tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters